scholarly journals P3-067: Clinical and molecular characteristics of advanced non-small cell lung cancer (NSCLC) patients (pts) with rapid progressive disease (RPD) on gefitinib therapy (G)

2007 ◽  
Vol 2 (8) ◽  
pp. S706-S707
Author(s):  
Mary J. Fidler ◽  
Lela Buckingham ◽  
Meryl Gale ◽  
John Coon Iv ◽  
Ann Mauer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progressive Disease ◽  
Small Cell ◽  
Molecular Characteristics ◽  
Small Cell Lung ◽  
Nsclc Patients

Monitoring immunotherapy response in non-small cell lung cancer patients using 5-hydroxymethylcytosine signatures in circulating cell free DNA.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21505-e21505
Author(s):  
Gulfem Guler ◽  
David Haan ◽  
Yuhong Ning ◽  
Jeremy Ku ◽  
Erin McCarthy ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progressive Disease ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Biopsy ◽  
Lung Cancer Patients ◽  
Free Dna ◽  
Nsclc Patients

e21505 Background: Liquid biopsies are gaining prominence for not only cancer diagnosis but also patient monitoring. Mutational signals derived from cell-free DNA (cfDNA) show promise to assess response to cancer treatment, including immunotherapy. However, reliance of these methods on mutational data from tissue biopsies limit their applicability when a tumor biopsy is unavailable, or when mutational landscape of tumor changes under the selective pressures of cancer drug treatment. Epigenomic approaches have the potential to address these shortcomings. Methods: Blood draws were obtained from a cohort of non-small cell lung cancer (NSCLC) patients (n = 19) who went on to anti-PD1 treatment prior to therapy start and while on therapy. cfDNA was isolated from plasma and was subsequently processed to generate 5hmC genome-wide profiles. Results: We analyzed cfDNA from NSCLC patients undergoing anti-PD1 therapy to investigate whether immunotherapy response can be detected from plasma. Using a predictive model trained on lung cancer and non-cancer samples, we were able to detect changes in prediction scores in patient treated with immunotherapy that were consistent with RECIST. Patients with progressive disease (n = 3), determined by RECIST, had prediction scores that increased while they received treatment. On the other hand, majority of the patients that exhibited partial response to treatment (n = 12) had predictive scores that decreased with treatment, again consistent with RECIST. Furthermore, score changes consistent with RECIST was observed one cycle prior to the RECIST timepoint in all except one patient, where an extra blood draw after baseline was available (n = 7). Annotation of the regions that account for differential scoring identified enhancer, 5’UTR and promoter regions. Comparison of partial responders to patients with progressive disease revealed genes involved in metastasis, oncogenes and tumor suppressors that change in opposing directions between these patient groups, consistent with the underlying biology. Conclusions: Our results suggest that 5hmC profiles from cfDNA can be used to determine immunotherapy response in non-small cell lung cancer patients. Compared with mutation based liquid biopsy methods to assess response, epigenomics-based methods have the advantage of being agnostic to starting tumor mutations, and not relying on a mutational analysis from tumor biopsy. Future work will help determine applicability of this method to other kinds of therapies and cancer types.

scholarly journals The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

2020 ◽  
Author(s):  
Ya Zeng ◽  
JianJiao Ni ◽  
Fan Yu ◽  
Yue Zhou ◽  
Yang Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Failure ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progressive Disease ◽  
Residual Disease ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients ◽  
Residual Lesions

Abstract Background: There was no study investigating real-world utilization and outcome of LCT in Osimertinib-treated NSCLC with oligo-residual disease. This study was to analyze the clinical value of local consolidative therapy (LCT) in Osimertinib-treated non-small cell lung cancer (NSCLC) patients with oligo-residual disease. Methods: Patients receiving standard Osimertinib treatment and developing oligo-residual disease (five or fewer residual metastatic lesions) were retrospectively reviewed. Local therapies performed to the oligo-residual tumor lesions or primary lung site before Osimertinib treatment failure were considered as LCT. Results: Of 108 patients recruited, first-line and second-line Osimertinib were administered in 25 and 83 patients, respectively, while LCT was performed in 14 patients. With a median follow-up of 43.6 months, 69 patients developed progressive disease. LCT significantly improved progression-free survival (PFS) (NR vs 12.8 months, p=0.01) and was independently associated with prolonged PFS (HR=0.29, 95%CI 0.12 to 0.68, p=0.004). Patients receiving LCT had a numerically longer overall survival (OS) (85.8 vs 77.1 months, p=0.58) and after adjusting for potentially confounding factors, LCT was associated with a non-significantly prolonged OS (HR=0.37, 95%CI 0.12-1.16, p=0.089). Pattern of failure analyses indicated that progressive disease developed at the originally existed oligo-residual lesions in 76.2% of the 63 patients who didn’t receive LCT and had Osimertinib treatment failure. Of note, 7 (70%) of the 10 patients who had oligo-residual cranial disease but didn’t receive LCT, developed more than five progressive lesions in the brain, which were no longer suitable for stereotactic radiosurgery. Conclusion: Among Osimertinib-treated NSCLC patients having oligo-residual lesions, LCT could improve local control and significantly increase PFS, which need to be verified by further investigations.

Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7025-7025 ◽  
Author(s):  
W. Pao ◽  
M. Zakowski ◽  
C. Cordon-Cardo ◽  
L. Ben-Porat ◽  
M. G. Kris ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Molecular Characteristics ◽  
Small Cell Lung ◽  
Nsclc Patients

Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7025-7025 ◽  
Author(s):  
W. Pao ◽  
M. Zakowski ◽  
C. Cordon-Cardo ◽  
L. Ben-Porat ◽  
M. G. Kris ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Molecular Characteristics ◽  
Small Cell Lung ◽  
Nsclc Patients

scholarly journals The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Ya Zeng ◽  
Jianjiao Ni ◽  
Fan Yu ◽  
Yue Zhou ◽  
Yang Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Failure ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progressive Disease ◽  
Residual Disease ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients ◽  
Residual Lesions

Abstract Background There was no study investigating real-world utilization and outcome of LCT in Osimertinib-treated NSCLC with oligo-residual disease. This study was to analyze the clinical value of local consolidative therapy (LCT) in Osimertinib-treated non-small cell lung cancer (NSCLC) patients with oligo-residual disease. Methods Patients receiving standard Osimertinib treatment and developing oligo-residual disease (five or fewer residual metastatic lesions) were retrospectively reviewed. Local therapies performed to the oligo-residual tumor lesions or primary lung site before Osimertinib treatment failure were considered as LCT. Results Of 108 patients recruited, first-line and second-line Osimertinib were administered in 25 and 83 patients, respectively, while LCT was performed in 14 patients. With a median follow-up of 43.6 months, 69 patients developed progressive disease. LCT significantly improved progression-free survival (PFS) (NR vs 12.8 months, p = 0.01) and was independently associated with prolonged PFS (HR = 0.29, 95%CI 0.12 to 0.68, p = 0.004). Patients receiving LCT had a numerically longer overall survival (OS) (85.8 vs 77.1 months, p = 0.58) and after adjusting for potentially confounding factors, LCT was associated with a non-significantly prolonged OS (HR = 0.37, 95%CI 0.12–1.16, p = 0.089). Pattern of failure analyses indicated that progressive disease developed at the originally existed oligo-residual lesions in 76.2% of the 63 patients who didn’t receive LCT and had Osimertinib treatment failure. Of note, 7 (70%) of the 10 patients who had oligo-residual cranial disease but didn’t receive LCT, developed more than five progressive lesions in the brain, which were no longer suitable for stereotactic radiosurgery. Conclusion Among Osimertinib-treated NSCLC patients having oligo-residual lesions, LCT could improve local control and significantly increase PFS, which need to be verified by further investigations.

scholarly journals The Value of Local Consolidative Therapy in Osimertinib-treated Non-small Cell Lung Cancer With Oligo-residual Disease

2020 ◽  
Author(s):  
Ya Zeng ◽  
JianJiao Ni ◽  
Fan Yu ◽  
Yue Zhou ◽  
Yang Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Failure ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progressive Disease ◽  
Residual Disease ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients ◽  
Residual Lesions

Abstract Background: There was no study investigating real-world utilization and outcome of LCT in Osimertinib-treated NSCLC with oligo-residual disease. This study was to analyze the clinical value of local consolidative therapy (LCT) in Osimertinib-treated non-small cell lung cancer (NSCLC) patients with oligo-residual disease.Methods: Patients receiving standard Osimertinib treatment and developing oligo-residual disease (five or fewer residual metastatic lesions) were retrospectively reviewed. Local therapies performed to the oligo-residual tumor lesions or primary lung site before Osimertinib treatment failure were considered as LCT.Results: Of 108 patients recruited, first-line and second-line Osimertinib were administered in 25 and 83 patients, respectively, while LCT was performed in 14 patients. With a median follow-up of 43.6 months, 69 patients developed progressive disease. LCT significantly improved progression-free survival (PFS) (NR vs 12.8 months, p=0.01) and was independently associated with prolonged PFS (HR=0.29, 95%CI 0.12 to 0.68, p=0.004). Patients receiving LCT had a numerically longer overall survival (OS) (85.8 vs 77.1 months, p=0.58) and after adjusting for potentially confounding factors, LCT tended to increase OS (HR=0.37, 95%CI 0.12-1.16, p=0.089). Pattern of failure analyses indicated that progressive disease developed at the originally existed oligo-residual lesions in 76.2% of the 63 patients who didn’t receive LCT and had Osimertinib treatment failure. Of note, 7 (70%) of the 10 patients who had oligo-residual cranial disease but didn’t receive LCT, developed more than five progressive lesions in the brain, which were no longer suitable for stereotactic radiosurgery. Conclusion: Among Osimertinib-treated NSCLC patients having oligo-residual lesions, LCT could significantly improve PFS and has a tendency to prolong OS, which need to be verified by further investigations.

Sign in / Sign up

Export Citation Format

Share Document